Form 4: Puma Biotech CFO Boosts Equity Holdings with New Awards

Puma Biotechnology's CFO, Maximo F. Nougues, received 46,739 Restricted Stock Units and 66,541 stock options as part of his compensation.

Summary

• Maximo F. Nougues, Chief Financial Officer of Puma Biotechnology, Inc. (PBYI), acquired 46,739 Restricted Stock Units (RSUs) on February 18, 2026.
• These RSUs will vest in four equal installments: one-fourth on July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, contingent on continued service.
• Following this transaction, Mr. Nougues beneficially owns 240,023 shares of Common Stock.
• Mr. Nougues also acquired 66,541 stock options on February 18, 2026, with an exercise price of $6.68 per share.
• The stock options will vest and become exercisable in four equal installments on the same dates as the RSUs: July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028, also subject to continued service.
• The expiration date for these stock options is February 17, 2036.
• Following this transaction, Mr. Nougues beneficially owns 66,541 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns management's interests with long-term shareholder value, which is generally favorable.

Positives

• The grant of equity awards aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing sustained performance.
• The acquisition of additional equity by a key executive demonstrates continued commitment to the company's future.

Negatives

• The equity awards are subject to vesting conditions, meaning the full benefit is not immediately realized and requires continued employment.
• The transaction does not represent an open market purchase, but rather compensation, which does not reflect a direct cash investment by the insider.

Risks

• The vesting of both Restricted Stock Units and stock options is contingent upon the Reporting Person's continued service with the Company through the applicable vesting dates, posing a risk to the full realization of the awards if service is terminated.

Future Outlook

The equity awards, with their multi-year vesting schedule extending to January 2028, indicate a long-term incentive structure designed to retain the Chief Financial Officer and align his performance with the company's sustained growth and shareholder value creation over the coming years.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units and stock options is a standard practice in executive compensation across the biotechnology and pharmaceutical industries. These equity-based incentives are commonly used to attract, retain, and motivate key management personnel by linking their compensation directly to the company's stock performance and long-term strategic objectives.

Stakeholder Impact

• Shareholders: The equity awards align the Chief Financial Officer's financial incentives with shareholder interests, potentially leading to more focused long-term strategic decisions.
• Employees: The continued commitment of a key executive like the CFO can signal stability and confidence in the company's future direction.

Next Steps

• The Chief Financial Officer must continue service with Puma Biotechnology, Inc. through the specified vesting dates (July 1, 2026, January 1, 2027, July 1, 2027, and January 1, 2028) to fully realize the granted Restricted Stock Units and stock options.

Key Dates

Keywords

PBYI, Puma Biotechnology, Maximo F. Nougues, Form 4, SEC filing, Restricted Stock Units, Stock Options, Insider Transaction, Executive Compensation, Equity Awards